Everything has been said on this BB...I understand that some find it frustrating to have to wait. As I mentionned so often in my posts, patience is the key.
When you hold an investment with SUCH a potential return and when you gather all the facts, you understand what AGN could be in a months time. There is a risk, as any other investment right now. You could be buying NA.TO or DOL.TO right now, and in months time be at the same SP than right now.
I don't believe that AGN is a ALL or NOTHING stock. The product has proven having significant positive results compared to other products trying to find the solution to COVID19 :
-Ifenprodil also outperformed Merck's phase 3 drug Gefapixant in a recent acute cough animal study by 110% (significant).
AGN has already proven surviability with regards to the Bird Flu, regarded as the most lethal flu (% of deaths/cases) :
An independent study found that Ifenprodil significantly reduced ALI and improved survivability in an animal study with Avian H5N1 infected mice by 40% (as a result Algernon has decided to expand its Ifenprodil clinical program to include ALI and COVID-19 - read more below). Avian H5N1 is the most lethal form of influenza known to man with an over 50% mortality rate.
These are proven facts that we know as of now. HC and FDA we given these positive preliminary findings and they gave back POSITIVE FEEDBACK. It is normal for HC and FDA to require official cases of COVID19 patients and see how they react to Ifenprodil (NP-120). Think about it, they wouldn't authorize the sale of drug to solve a problem without being sure it works.
You can have the money to do the research, you can be a company with a market cap of 100 billion $, but it's ALL about the PRODUCT you have. AGN does have the product, and I feel alot more confident about Ifenprodil than any other drug being created right now in a lab, because there is a RISK that the drug has negative effects (provoque other sicknesses, death, etc).
Ifenprodil has been around for decades, therefore we can cross out that risk of our list. We start off with one big step in front of all the other Bio companies.
David